- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04955197
Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions
Accuracy of Exfoliated Cytology in Detection of Oral Premalignant and Malignant Lesions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be held at the Faculty of Dentistry Cairo University and the NCI All the participants will be administrated a standardized questionnaire to obtain demographic data, medical records and any history of relevant risk factors. The detailed clinical examination will be performed on each patient to assess the site, size, and the clinical characteristics of the lesion as well as the extent of local infiltration (if any) and cervical lymph node metastases (if any).
The entire procedure will be explained to the patients and an informed consent will be obtained. The participants were asked to rinse their mouth thoroughly with tap water 2-3 times immediately before the sampling procedure to reduce the oral bacterial load. Pre-moistened separate wooden spatula was used to scrape the oral buccal mucosa cells (right and left buccal mucosal cells). The cells were then smeared over clean, coded glass slides. The slides were then air dried and fixed in fixative for 20 minutes and stained. Afterwards the glass slide was rinsed with aqua dest and dried in the air. The slides will be prepared for microscopic analysis The criteria parameters for identifying micronucleus:
- Rounded smooth perimeter suggestive of a membrane.
- Less than one-third the diameter of the associated nucleus, but large enough to discern shape and color.
- Staining intensity similar to the nucleus.
- Texture similar to the nucleus.
- Same focal plane as the nucleus.
- Absence of overlap with or bridge to the nucleus.
Dead or degenerating cells (karyolysis, karyorrhexis, nuclear fragmentation) were excluded from the evaluation. Incisional or excisional biopsy will be obtained from subjects diagnosed with premalignant lesions and histo-pathological examination will be performed as an additional supportive test .
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: alaa elnaggar, MSD
- Phone Number: 01007802767
- Email: alaa_hassan@dentistry.cu.edu.eg
Study Contact Backup
- Name: Gihane madkour, professor
- Email: gihanemadkour@gmail.com
Study Locations
-
-
-
Cairo, Egypt, 11865
- Recruiting
- Faculty of Dentistry
-
Contact:
- alaa elnaggar, Master
- Phone Number: 01007802767
- Email: alaa_hassan@dentistry.cu.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Participants with clinically normal oral mucosa and no evidence of any cancer risk factor as smoking and alcohol consumption.Participants with clinically normal oral mucosa and with evidence of any cancer risk factor as smoking and alcohol consumption. Participants with potentially malignant (leukoplakia, oral lichen planus, smoker keratosis and erythroplakia) Participants diagnosed with malignant disorders.
• All age range will be included irrespective of their sex.
Description
Inclusion Criteria:
- Control group I: Participants with clinically normal oral mucosa and no evidence of any cancer risk factor as smoking and alcohol consumption.
- Control group II: Participants with clinically normal oral mucosa and with evidence of any cancer risk factor as smoking and alcohol consumption.
- Compare group III: Participants with potentially malignant lesions
- Compare group IV: Participants diagnosed with malignant disorders.
- All age range will be included irrespective of their sex.
Exclusion Criteria:
• Individuals who had a recent viral infection or had undergone radiation therapy.
- Those patients were excluded from the control group who had any history of tobacco intake or alcohol consumption and under medications.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
the histo-pathological picture
In the present study, the exfoliated cytology of group II and III will be compared to the histo-pathological picture of the lesion "reference standard".
That is because the histopathology analysis is the definitive diagnosis of oral mucosal lesions
|
Micronuclei (MN) are small chromatin bodies in the cytoplasm formed by chromosome fragments or whole chromosomes that fail to be included in the nuclei during cell division.
They are considered as a sensitive indicators of genetic damage.
They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation.
Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions.
Consequently, detection of micronuclei in exfoliated cells indicates an increased risk for cancer
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Micronuclei presence
Time Frame: 5 minutes
|
a sensitive indicators of genetic damage.
They are usually found in the basal cells of epidermis and are shed as exfoliated cells on maturation.
Hence micronuclei assay can be used as monitoring of genetic damage, as it is increased in oral neoplastic conditions.
|
5 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: alaa elnaggar, MSD, Cairo University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- cancer screening
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diagnoses Disease
-
Institut CurieInstitut Mutualiste MontsourisRecruitingDiagnoses Disease | Bronchopulmonary DiseaseFrance
-
Inspirata Europe Ltd.CompletedDiagnoses DiseaseUnited Kingdom
-
Shanghai Chest HospitalUnknownDiagnoses DiseaseChina
-
University of ExeterCompleted
-
Nazan Kocak TopbasMersin UniversityNot yet recruiting
-
Brigham and Women's HospitalCricoCompleted
-
Istanbul Bilgi UniversityUnknown
-
Hospital do CoracaoCompletedInpatient Facililty DiagnosesBrazil
-
Institute of Liver and Biliary Sciences, IndiaCompleted
-
Nagaoka Red Cross HospitalUnknownOther Diagnoses and ConditionsJapan
Clinical Trials on exfoliated cytology
-
CAR-T (Shanghai) Biotechnology Co., Ltd.Unknown
-
Institute of Liver and Biliary Sciences, IndiaUnknown
-
Changhai HospitalUnknownDiagnoses Disease | Urothelial Carcinoma | Chromosomal Abnormality | Urine MarkingChina
-
Qilu Hospital of Shandong UniversityRecruitingProstate CarcinomaChina
-
Changhai HospitalRenJi Hospital; West China Hospital; Tongji Hospital; Qilu Hospital of Shandong... and other collaboratorsRecruitingUrothelial CarcinomaChina
-
Institut Paoli-CalmettesCompleted
-
Bezmialem Vakif UniversityCompletedGastric Cancer | Gastric AdenocarcinomaTurkey
-
Peking University People's HospitalJiangsu HengRui Medicine Co., Ltd.; OrigiMedCompleted
-
CAR-T (Shanghai) Biotechnology Co., Ltd.Completed
-
University of AthensCompletedCholangiocarcinoma | Endoscopic SphincterotomyGreece